WHO Preferred Product Characteristics: Next-Generation Influenza Vaccines
Overview
Led technical analysis and drafting of updated WHO Preferred Product Characteristics for next-generation influenza vaccines, integrating evidence from the vaccine development pipeline, public health needs, WHO influenza guidance, global R&D targets, and lessons learned from the COVID-19 pandemic
Role
Technical lead and primary drafting author for the update of WHO Preferred Product Characteristics for next-generation influenza vaccines, working with an international group of vaccine experts and WHO colleagues.
Key Contributions & Outputs
• Drafted the initial update of WHO Preferred Product Characteristics document for next-generation influenza vaccines, integrating evidence from the vaccine development pipeline, public health needs, WHO influenza guidance, global R&D targets for improved influenza vaccines, and lessons learned from the COVID-19 pandemic
• Co-led working group discussions with international vaccine experts to review and refine proposed product characteristics
• Synthesized expert feedback and contributed to revisions of the WHO guidance document
• Collaborated with WHO colleagues in the development and finalization of the updated PPC guidance
Impact
The updated PPCs provide global guidance to vaccine developers, funders, and policymakers working to advance next-generation influenza vaccines and strengthen pandemic influenza preparedness.